Australia's most trusted
source of pharma news
Saturday, 10 May 2025
Posted 7 May 2025 PM
Teva Pharma’s prophylactic migraine treatment Ajovy could also help reduce symptoms of depression, a new international study published in JAMA Neurology has found.
The team of researchers led by the Albert Einstein College of Medicine in the US say that their UNITE study is the first-ever placebo-controlled, randomised clinical trial to demonstrate significant improvements in migraine and depressive symptoms with a single drug.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.